Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. American Psychiatric Publishing; 2013.
   Google Scholar
• American Psychiatric Association (APA). Practice Guideline for the Treatment of Patients with Schizophrenia. American Psychiatric Association (APA); 2021.
   Google Scholar
• Desai PR, Lawson KA, Barner JC, Rascati KL. Estimating the direct and indirect costs for community-dwelling patients with schizophrenia. J Pharm Health Services Res. 2013;4(4):187–194. doi:10.1111/jphs.12027
   Google Scholar
• Kessler RC, Birnbaum H, Demler O, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005;58(8):668–676. doi:10.1016/j.biopsych.2005.04.034
   PubMed Web of Science ®Google Scholar
• Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535–1540. doi:10.1017/S0033291706008191
   PubMed Web of Science ®Google Scholar
• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. doi:10.1038/nrdp.2015.67
   PubMed Web of Science ®Google Scholar
• Pilon D, Tandon N, Lafeuille M-H, et al. Treatment patterns, health care resource utilization, and spending in Medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical antipsychotics. Clin Ther. 2017;39(10):1972–1985. doi:10.1016/j.clinthera.2017.08.008
   PubMed Web of Science ®Google Scholar
• Pilon D, Muser E, Lefebvre P, Kamstra R, Emond B, Kruti J. Adherence, healthcare resource utilization and Medicaid spending associated with once monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry. 2017;17(1):207. doi:10.1186/s12888-017-1358-3
   PubMed Web of Science ®Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554–561. doi:10.4088/JCP.14m09584
   PubMed Web of Science ®Google Scholar
• University of South Florida, Florida Medicaid Drug Therapy Management Program sponsored by the Florida Agency for Health Care Administration. 2019-2020 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults. 2020; 1–78. Available from: https://floridabhcenter.org/wp-content/uploads/2021/04/2019-Psychotherapeutic-Medication-Guidelines-for-Adults-with-References_06-04-20.pdf. Accessed July 1, 2022.
   Google Scholar
• El Khoury A, Patel C, Huang A, Wang L, Bashyal R. Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization. Curr Med Res Opin. 2019;35(12):2159–2168. doi:10.1080/03007995.2019.1651129
   PubMed Web of Science ®Google Scholar
• Joshi K, Lafeuille MH, Kamstra R, et al. Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits. J Comp Eff Res. 2018;7(2):121–133. doi:10.2217/cer-2017-0043
   PubMed Web of Science ®Google Scholar
• Mental Health Clinical Advisory Group, Oregon Health Authority. Mental Health Care Guide for Licensed Practitioners and Mental Health Professionals. Mental Health Clinical Advisory Group, Oregon Health Authority; 2019.
   Google Scholar
• Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115(4):260–267. doi:10.1111/j.1600-0447.2006.00982.x
   PubMed Web of Science ®Google Scholar
• Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30(8):689–701. doi:10.1007/s40263-016-0350-7
   PubMed Web of Science ®Google Scholar
• Olayinka O, Oyelakin A, Cherukupally K, et al. Use of long-acting injectable antipsychotic in an inpatient unit of a community teaching hospital. Psychiatry J. 2019;2019:8629030. doi:10.1155/2019/8629030
   Google Scholar
• Robinson DG, Schooler NR, John M, et al. Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry. 2015;172(3):237–248. doi:10.1176/appi.ajp.2014.13101355
   PubMed Web of Science ®Google Scholar
• Potkin S, Bera R, Zubek D, Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry. 2013;13:261. doi:10.1186/1471-244X-13-261
   PubMed Web of Science ®Google Scholar
• Li G, Keenan A, Daskiran M, et al. Relapse and treatment adherence in patients with schizophrenia switching from paliperidone palmitate once-monthly to three-monthly formulation: a retrospective health claims database analysis. Patient Prefer Adherence. 2021;15:2239–2248. doi:10.2147/PPA.S322880
   PubMed Web of Science ®Google Scholar
• Gannon J, Conlogue J, Sherwood R, et al. Long acting injectable antipsychotic medications: ensuring care continuity during the COVID-19 pandemic restrictions. Schizophr Res. 2020;222:532–533. doi:10.1016/j.schres.2020.05.001
   PubMed Web of Science ®Google Scholar
• Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 global pandemic: implications for people with schizophrenia and related disorders. Schizophr Bull. 2020;46(4):752–757. doi:10.1093/schbul/sbaa051
   PubMed Web of Science ®Google Scholar
• Lin J, Wong B, Offord S, Mirski D. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Res. 2013;40(3):355–366. doi:10.1007/s11414-013-9329-z
   Web of Science ®Google Scholar
• Schreiner A, Svensson A, Wapenaar R, et al. Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). World J Biol Psychiatry. 2014;15(7):534–545. doi:10.3109/15622975.2014.902990
   PubMed Web of Science ®Google Scholar
• Shah A, Xie L, Kariburyo F, Zhang Q, Gore M. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. Adv Ther. 2018;35(11):1994–2014. doi:10.1007/s12325-018-0786-x
   PubMed Web of Science ®Google Scholar
• Pietrini F, D’Anna G, Tatini L, et al. Changes in attitude towards LAI antipsychotic maintenance treatment: a two-year follow-up study. Eur Psychiatry. 2018;53:58–65. doi:10.1016/j.eurpsy.2018.06.002
   PubMed Web of Science ®Google Scholar